
    
      Patients are randomized to 1 of 2 groups. Group 1 receives 3TC qd plus d4T plus either IDV or
      NFV. Group 2 receives 3TC bid plus d4T plus either IDV or NFV. Patients are evaluated for
      drug tolerance, medication adherence, and genotypic and phenotypic resistance.
    
  